Affiliations: [a] Department of Pharmacology, Wayne State University, Detroit, MI, USA
| [b] Functional Fluidics, Detroit, MI, USA
| [c]
Emory University, Atlanta, GA, USA
| [d] Blaze Medical Devices, Ann Arbor, MI, USA
| [e] Mast therapeutics, Inc., San Diego, CA, USA
| [f] Critical Care Medicine, Children’s Hospital of Michigan, Detroit, MI, USA
Correspondence:
[*]
Corresponding author: Patrick Hines, MD/Ph.D., 3901 Beaubien, Blvd., Suite 4134, Detroit, MI, USA. Tel.: +1 313 745 629; Fax: +1 313 996 0105; Email: [email protected].
Abstract: BACKGROUND:Red blood cell (RBC)-modifying therapies have provided new opportunities for patients with sickle cell disease, although the absence of validated biomarkers of RBC function is a barrier to FDA approval and clinical adoption. Flow Adhesion (FA) and Mechanical Fragility (MF) biomarkers objectively stratify individuals with SCD into pro-adhesive vs pro-hemolytic phenotypes respectively, which may potentially help predict therapeutic responses. OBJECTIVE:A Phase 3 clinical trial to determine the effectiveness of vepoloxamer, an RBC-modifying therapy in sickle cell disease (SCD), failed to meet its primary clinical outcome. The aim of this study was to determine whether standardized flow adhesion and mechanical fragility bioassays could differentiate cellular level “responders” from “non-responders” to vepoloxamer treatment. METHODS:Standardized biomarkers of RBC function (adhesion and mechanical fragility) were utilized in this study to assess the effect of veploxamer on blood samples collected from SCD subjects and to determine whether our assays could differentiate cellular-level “responders” from “non-responders” to vepoloxamer treatment. A Wilcoxon signed-rank test was used to test for differences in adhesion in response to varying vepoloxamer treatments and a Wilcoxon Mann-Whitney test was used to assess differences in mechanical fragility, pre- and post-vepoloxamer treatment. A p-value<0.05 was considered significant. RESULTS:In this study, we report that in vitro treatment with vepoloxamer reduced adhesion by >75%in 54%of patient samples and induced changes in the membranes of sickle erythrocytes (SSRBCs) making sickle cells behave more like normal erythrocytes (AARBCs) in terms of their resistance to hemolysis. CONCLUSION:This study demonstrates that the standardized flow adhesion and mechanical fragility biomarkers described here may be useful tools to predict clinical responders to RBC-modifying therapies.
